©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2025; 31(3): 98783
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.98783
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.98783
Elafibranor: A promising therapeutic approach for liver fibrosis and gut barrier dysfunction in alcohol-associated liver disease
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei City 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Co-corresponding authors: Wen-Rui Hao and Tzu-Hurng Cheng.
Author contributions: Cheng CH, Hao WR, and Cheng TH have contributed to this article; Cheng CH and Hao WR primarily responsible for writing; Cheng TH overseeing revisions; Hao WR and Cheng TH refined the final manuscript in their respective areas of specialization, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: July 5, 2024
Revised: November 18, 2024
Accepted: December 2, 2024
Published online: January 21, 2025
Processing time: 167 Days and 20 Hours
Revised: November 18, 2024
Accepted: December 2, 2024
Published online: January 21, 2025
Processing time: 167 Days and 20 Hours
Core Tip
Core Tip: This article highlights the major findings of the study written by Koizumi et al. The study demonstrated the potential of elafibranor, a peroxisome proliferator-activated receptor agonist, in mitigating liver fibrosis and improving gut barrier integrity in a mouse model of alcohol-associated liver disease. These findings underscore the promising therapeutic potential of elafibranor and its relevance in advancing treatment strategies for liver diseases linked to chronic alcohol consumption.